EGFR-binding molecules and immunoconjugates thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9125896
APP PUB NO 20140099308A1
SERIAL NO

13800624

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • IMMUNOGEN, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chittenden, Thomas Sudbury, US 19 148
Park, Peter U Somerville, US 36 400
Payne, Gillian Waban, US 28 457
Rui, Lingyun Weston, US 44 495
Setiady, Julianto Waltham, US 16 112

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 8, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00